Welcome to This Is MS!

     Modules
· Home
· Content
· Downloads
· Encyclopedia
· FAQ
· Feedback
· Forums
· Journal
· Private Messages
· Recommend Us
· Search
· Site_Map
· Stories Archive
· Submit News
· Surveys
· Top 10
· Topics
· Web Links
· Your Account

     Google
Google
Web
This is MS
These ads help pay for the upkeep of our site. They are automatically served by Google and are not affiliated with This is MS.

     Languages
Select Interface Language:


     Who's Online
There are currently, 250 guest(s) and 7 member(s) that are online.

You are Anonymous user. You can register for free by clicking here

     Next Step

From the creators of This is MS comes Experience Project

EP is a community where members connect through shared life experiences-- like MS--and so much more. You are not defined by any one thing, so be your true self and find others just like you at Experience Project.

Get started by sharing your Multiple Sclerosis story.


     Donations

To remain unbiased, This is MS does not accept corporate sponsorships.

Therefore, we must rely on our users to help support us. Please donate to our upkeep if you have the means. Thank you!


 Elan Shows More Faith in Antegren

Antegren

Elan just sold off two of its established drugs in favor of funding its pipeline-- in other words, they are collecting their cash to put the big bets on two drugs they think will be huge, particularly Antegren for MS. This is yet another positive for people hopeful that Antegren will be the next great MS treatment.

"DUBLIN, March 31 (Reuters) - Irish drugmaker Elan Corp has agreed to sell its North American and European interests in epilepsy treatment Zonegran to Japan's Eisai Co Ltd (for about $130 million, the company said on Wednesday.

Elan, which has hauled itself back from the brink of bankruptcy in 2002, said the deal would allow it to focus on the expected 2005 launch of two key drugs, Antegren for multiple sclerosis (MS) and Crohn's disease, and Prialt for severe pain...

"Elan is reverting to a pure play on its pipeline with the strategic disposal of Zonegran coming only hours after the sale of Frova," said Jack Gorman, analyst at Davy Stockbrokers, adding Elan was likely to use the cash to prepare its marketing infrastructure for the launch of Antegren and Prialt.

Some analysts estimate the MS market alone could be worth more than $6 billion by 2010 and that Elan's Antegren could take a 40 percent slice of it."

Sourced from: here

Advertisement

 




 
     Login
Nickname

Password

Don't have an account yet? You can create one. As a registered user you have some advantages like theme manager, comments configuration and post comments with your name.

     Related Links
· More about Antegren
· News by Administrator


Most read story about Antegren:
Antegren could be here sooner than we thought...


     Article Rating
Average Score: 0
Votes: 0

Please take a second and vote for this article:

Excellent
Very Good
Good
Regular
Bad


     Options

 Printer Friendly Printer Friendly






Personal Stories about millions of life experience--including multiple sclerosis support, lupus support, depression support . Built by the This is MS team.

Anonymous Confessions | Dream Dictionary
Site Map

This site does not offer medical advice. All treatment decisions should always be made with the full consent of your physician.


Visit our sister site dedicated to Inflammatory Bowel Disease: This is IBD


All logos and trademarks in this site are property of their respective owners. The comments are property of their posters, quoted articles are © referenced source, all the rest © 2002 by thisisMS.com.
PHP-Nuke Copyright © 2005 by Francisco Burzi. This is free software, and you may redistribute it under the GPL. PHP-Nuke comes with absolutely no warranty, for details, see the license.
Page Generation: 0.11 Seconds